Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bumyong Lee

Psychiatry Danville, IL Medical Doctor

NPI 1487661930 CMS profile 249364

210 Avenue C, Danville, IL 61832

Open in the dashboard

General payments

$25,355

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bumyong Lee of Danville, IL is reported in the CMS Open Payments database as having received $25,355 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $114 6
2023 General $426 24
2022 General $951 58
2021 General $600 41
2020 General $5,316 31
2019 General $17,949 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bumyong Lee
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Bumyong Lee were reported at $114. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Bumyong Lee Psychiatry median Middle half National median
2019 $17,949 $184 $59–$605 $163
2020 $5,316 $119 $36–$372 $114
2021 $600 $143 $43–$576 $132
2022 $951 $153 $50–$590 $149
2023 $426 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $114 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $22,730 60 payments
  2. Janssen Pharmaceuticals, Inc $644 47 payments
  3. Alkermes, Inc. $614 31 payments
  4. Otsuka America Pharmaceutical, Inc. $583 41 payments
  5. Neurocrine Biosciences, Inc. $291 13 payments
  6. ITI, Inc. $175 12 payments
  7. AbbVie, Inc. $148 8 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $59 3 payments
  9. Teva Pharmaceuticals USA, Inc. $47 2 payments
  10. Shire North American Group Inc $31 2 payments
  11. Other $35 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,454 11 payments
  2. Food and Beverage $3,325 194 payments
  3. Travel and Lodging $1,565 14 payments
  4. Education $11 2 payments
Products named General payments · program years 2019–2025
  1. LATUDA $22,730 60 payments
  2. ARISTADA Cns $614 31 payments
  3. ARISTADA Cns $614 31 payments
  4. INVEGA SUSTENNA $545 45 payments
  5. ABILIFY MAINTENA $543 39 payments
  6. ARISTADA INITIO $522 26 payments
  7. LYBALVI $361 20 payments
  8. ARISTADA Cns $345 16 payments
  9. ARISTADA Cns $345 16 payments
  10. REXULTI $316 21 payments
  11. Other $1,509 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,004

Median for Psychiatry: 574

Drug cost

$183,781

Median for Psychiatry: $27,624

Branded share of claims

19.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 21 $62,618
Lurasidone Hcl Generic 81 $57,402
Invega Sustenna Paliperidone Palmitate Brand 13 $34,617
Rexulti Brexpiprazole Brand 11 $15,252
Quetiapine Fumarate Generic 157 $2,582
Clozapine Generic 25 $2,484
Divalproex Sodium Er Divalproex Sodium Brand 47 $2,256
Haloperidol Generic 19 $1,125
Alprazolam Generic 53 $684
Divalproex Sodium Generic 16 $540

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$8,762

Medicare's payments for the services billed

Medicare patients

27

Average age 64

Services billed

107

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Depression 52%
Diabetes 44%
COPD 41%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record